S. Hearn

Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer

J. von Pawel, J. Pujol, G. Ross, 2001, Oncology.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I P harmacologic S tudy o f O ral T opotecan a nd Intravenous C isplatin: S equence-Depende nt H ematologic Side E ffects

J. Verweij, H. Gelderblom, A. Sparreboom, 2000 .

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of oral topotecan in advanced non-small cell lung cancer.

M. Ranson, N. Thatcher, B. Carrington, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

M. Gore, G. Rustin, R. Beckman, 2001, British Journal of Cancer.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.